Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study Hematologic Malignancy

Conclusion In this phase I study of relapsed/refractory NHL, continuous infusion with CD19-targeted immunotherapy blinatumomab at various doses and schedules was feasible, with an MTD of 60 μg/m2/day. Single-agent blinatumomab showed antilymphoma activity.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Clinical Trials, Phase I and Clinical Pharmacology, Translational Oncology, Hematologic Hematologic Malignancy Source Type: research

Related Links:

The objective of this review is to provide a comprehensive summary of ICANS and strategies for prompt identification and management of patients presenting to the intensive care unit with this syndrome.
Source: Critical Care Nursing Quarterly - Category: Nursing Tags: Original Articles Source Type: research
Chimeric antigen receptor (CAR)-T cell therapy is a new and powerful class of cancer immunotherapy [1,2]. Clinical trials of CAR-T cell therapy targeting the B cell marker CD19 have shown promising results for the treatment of hematologic malignancies, including acute lymphoblastic leukemia (ALL) [3-7], chronic lymphocytic leukemia [8,9], and non-Hodgkin lymphoma (NHL) [10,11]. CAR-T cell therapy targeting B cell maturation antigen (BCMA) has also been demonstrated to be effective for treating multiple myeloma (MM) [12-15].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Chimeric antigen receptor (CAR)-T cell therapy is a new and powerful class of cancer immunotherapy [1,2]. Clinical trials of CAR-T cell therapy targeting the B-cell marker CD19 have shown promising results for the treatment of hematologic malignancies, including acute lymphoblastic leukemia (ALL) [3 –7], chronic lymphocytic leukemia (CLL) [8,9], and non-Hodgkin lymphoma (NHL) [10,11]. CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has also been demonstrated to be effective for treating multiple myeloma (MM) [12–15].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Abstract Adoptive immunotherapy of cancer using T cells expressing chimeric antigen receptors (CARs) is now an approved treatment for non-Hodgkin lymphoma (NHL) and B cell acute lymphoblastic leukemia (B-ALL), inducing high response rates in patients. The infusion products are generated by using retro- or lentiviral transduction to induce CAR expression in T cells followed by an in vitro expansion protocol. However, use of viral vectors is cumbersome and is associated with increased costs due to the required high titers, replication-competent retrovirus (RCR) detection and production/use in a biosafety level 2 cul...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
AbstractPurpose of ReviewThe US Food and Drug Administration (FDA) approved two commercially available chimeric antigen receptor (CAR) T cell therapies for the treatment of relapsed B cell acute lymphoblastic leukemia (B-ALL) children and young adults less than 25  years of age and non-Hodgkin lymphoma in adults after promising results from early-phase single and multi-institutional clinical trials. In this review, we provide an overview of the practical aspects of a chimeric antigen T cell receptor (CAR-T) program development and the steps necessary for its successful implementation.Recent FindingsCAR-T therapy is a ...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
CD19-targeted chimeric antigen receptor modified T-cell immunotherapy (CD19 CAR T cells) has shown excellent antitumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [1] and non-Hodgkin lymphoma (NHL) [2,3], which led to the approval of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) by regulatory agencies in the United States, Europe, Canada, Japan, and Australia. This approval has transformed the care of patients with relapsed/refractory ALL and aggressive B cell NHL [4-6].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
CD19-targeted chimeric antigen receptor modified T-cell immunotherapy (CD19 CAR-T cells) has shown excellent anti-tumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [1] and non-Hodgkin lymphoma (NHL) [2,3], which led to the approval of tisagenlecleucel (Kymriah ࣨ) and axicabtagene ciloleucel (Yescartaࣨ) by regulatory agencies in the United States, Europe, Canada, Japan and Australia. This approvalhas transformed the care of patients with relapsed/refractory ALL and aggressive B cell NHL [4-6].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CD19-targeted chimeric antigen receptor-modified T cell (CAR-T cell) immunotherapy has shown excellent antitumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [2] and non-Hodgkin lymphoma (NHL) [3,4], which has led to the approval of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) by the US Food and Drug Administration (FDA).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Hematology | Immunotherapy | Leukemia | Lymphoma | Neurology | Non-Hodgkin's Lymphoma | Study